Authors:
BLAISE D
JOURDAN E
FEGUEUX N
MICHALLET M
REIFFERS J
JOUET JP
MICHEL G
FAUCHER C
FORTANIER C
SCHULLER MP
BADRI N
CHABANNON C
MARANINCHI D
Citation: D. Blaise et al., IMPACT OF ALLOGENEIC PBSC TRANSPLANTATION IN A POPULATION OF STANDARDRISK PATIENT, Bone marrow transplantation, 21, 1998, pp. 103-103
Authors:
BLAISE D
JOURDAN E
FEGUEUX N
MICHALLET M
REIFFERS J
JOUET JP
MICHEL G
FAUCHER C
FORTANIER C
SCHULLER MP
BADRI N
CHABANNON C
MARANINCHI D
Citation: D. Blaise et al., IMPACT OF ALLOGENEIC PBSC TRANSPLANTATION IN A POPULATION OF STANDARDRISK PATIENT, Bone marrow transplantation, 21, 1998, pp. 147-147
Authors:
CARELLA AM
SIMONSSON B
LINK H
LENNARD A
BOOGAERTS M
GORIN NC
TOMASMARTINEZ JF
DABOUZHARROUCHE F
GAUTIER L
BADRI N
Citation: Am. Carella et al., MOBILIZATION OF PHILADELPHIA-NEGATIVE PERIPHERAL-BLOOD PROGENITOR CELLS WITH CHEMOTHERAPY AND RHUG-CSF IN CHRONIC MYELOGENOUS LEUKEMIA PATIENTS WITH A POOR RESPONSE TO INTERFERON-ALPHA, British Journal of Haematology, 101(1), 1998, pp. 111-118
Authors:
GATZEMEIER U
THOMAS P
CARDENAL F
SNIJDER RJ
SAMARAS N
MELO MJ
AUMANN J
HERMANN R
PUGANIGG K
BADRI N
Citation: U. Gatzemeier et al., PRELIMINARY-RESULTS OF A RANDOMIZED PHASE-III TRIAL OF AN ESTABLISHEDCHEMOTHERAPY (CT) REGIMEN WITH OR WITHOUT LENOGRASTIM (RHUG-CSF) IN SMALL-CELL LUNG-CANCER (SCLC) - IMPACT ON SURVIVAL, European journal of cancer, 33, 1997, pp. 1033-1033
Authors:
LINK H
WANDT H
SCHONROCKNABULSI P
EHNINGER G
FRANKE A
GACKLE R
GEER T
STROBEL G
LINKESCH W
KRIEGER O
NIEDERWIESER D
NIKIFORAKIS E
OHL S
OTREMBA B
PITTERMANN E
SCHMIDT H
TISCHLER J
WEISS J
WILHELM M
BADRI N
Citation: H. Link et al., G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED RANDOMIZED TRIAL, Experimental hematology, 25(8), 1997, pp. 35-35
Authors:
BLAISE D
JOURDAN E
FEGUEUX N
MICHALLET M
REIFFERS J
JOUET JP
MICHEL G
FAUCHER C
FORTANIER C
HUA A
SCHULLER MP
BADRI N
CHABANNON C
MARANINCHI D
Citation: D. Blaise et al., LENOGRASTIM AS A PRIMING AGENT FOR ALLOGENEIC STEM-CELL TRANSPLANTATION, Experimental hematology, 25(8), 1997, pp. 325-325
Authors:
LINK H
WANDT H
SCHONROCKNABULSI P
EHNINGER G
FRANKE A
GACKLE R
GEER T
STROBEL G
LINKESCH W
KRIEGER O
NIEDERWIESER D
NIKIFORAKIS E
OHL S
OTREMBA B
PITTERMANN E
SCHMIDT H
TISCHLER J
WEISS J
WILHELM M
BADRI N
Citation: H. Link et al., G-CSF (LENOGRASTIM) AFTER CHEMOTHERAPY FOR ACUTE MYELOID-LEUKEMIA - APLACEBO-CONTROLLED TRIAL, Blood, 88(10), 1996, pp. 2654-2654
Authors:
HAROUSSEAU JL
FACON T
MALOISEL F
DABOUZHARROUCHE F
WITZ F
GUILHOT F
ARCHIMBAUD E
DESABLENS B
ABGRALL JF
LINASSIER C
GROSBOIS B
BANCILLON A
BADRI N
BATAILLE R
Citation: Jl. Harousseau et al., G-CSF INSTEAD OF AUTOLOGOUS STEM-CELL TRANSPLANTATION AFTER HIGH-DOSEMELPHALAN AS FRONT-LINE THERAPY IN MULTIPLE-MYELOMA, Blood, 86(10), 1995, pp. 725-725
Authors:
DEPIERRE A
CHASTANG C
QUOIX E
LEBEAU B
BLANCHON F
PAILLOT N
LEMARIE E
MILLERON B
MORO D
CLAVIER J
HERMAN D
TUCHAIS E
JACOULET P
BRECHOT JM
CORDIER JF
SOLALCELIGNY P
BADRI N
BESENVAL M
Citation: A. Depierre et al., VINORELBINE VERSUS VINORELBINE PLUS CISPLATIN IN ADVANCED NONSMALL CELL LUNG-CANCER - A RANDOMIZED TRIAL, Annals of oncology, 5(1), 1994, pp. 37-42